The Efficeon TM8800 is manufactured in a 90-nm CMOS process technology at Fujitsu Electronics Devices Group Akiruno Advanced Technology Center near Tokyo, Transmeta said.

Transmeta's total revenue for the third quarter ending September 24, 2004 is now projected to be between $6.8 million and $7.5 million. This total includes projected product revenue of between $3.1 million and $3.8 million, and expected license revenue of about $3.5 million from Transmeta's first LongRun2(TM) licensing partner for the transfer of LongRun2 technologies. License revenue for the third quarter may vary depending upon final acceptance of Transmeta's completed deliverables.

This updated outlook compares with the Company's earlier projection, made in connection with the release of its second quarter results, that its third quarter revenue would be between $8.0 and $8.7 million, about $3.5 million of which was expected from Transmeta's first LongRun2 licensing partner for the transfer of LongRun2 technologies.

"Our achievement of limited production has enhanced our product position, but our current quarter sales will reflect our constrained product availability as we moved through our 90-nm product qualification process," said Matthew Perry, Transmeta president and chef executive officer, in a statement. "In addition, our sales will be significantly affected by softening demand in the enterprise sector and by our customers' product lifecycle-related transitions within their Transmeta-based product lines."